Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$90.00 +1.4%	$67.34	$52.50 ▼ $90.23	$1.92B	0.61	623,678 shs	604,501 shs
ARQT Arcutis Biotherapeutics	$15.98 +2.2%	$14.43	$8.03 ▼ $17.75	$1.87B	1.84	1.71 million shs	2.48 million shs
SLDB Solid Biosciences	$6.17 -7.6%	$5.59	$2.41 ▼ $10.37	$520.16M	2.44	1.54 million shs	1.33 million shs
VCEL Vericel	$35.77 -5.7%	$39.86	$33.09 ▼ $63.00	$1.91B	1.27	636,981 shs	442,842 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	+1.42%	+30.42%	+40.63%	+50.03%	+52.03%
ARQT Arcutis Biotherapeutics	+2.24%	+13.17%	+3.77%	+13.25%	+66.81%
SLDB Solid Biosciences	-7.63%	-0.32%	+14.47%	+122.74%	-26.11%
VCEL Vericel	-5.69%	-1.05%	-3.58%	-15.80%	-21.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.4129 of 5 stars	1.5	1.0	3.3	3.8	3.3	1.3
ARQT Arcutis Biotherapeutics	1.6344 of 5 stars	2.4	2.0	0.0	2.7	1.7	0.6
SLDB Solid Biosciences	3.5131 of 5 stars	4.6	2.0	0.0	3.1	1.7	0.6
VCEL Vericel	2.4615 of 5 stars	3.5	0.0	0.0	3.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$84.75	-5.83% Downside
ARQT Arcutis Biotherapeutics	2.86	Moderate Buy	$19.80	23.90% Upside
SLDB Solid Biosciences	3.17	Buy	$15.00	143.11% Upside
VCEL Vericel	3.00	Buy	$60.33	68.67% Upside

Current Analyst Ratings Breakdown

Latest SLDB, ANIP, ARQT, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/14/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $13.00
8/13/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $14.00
8/11/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$65.00 ➝ $77.00
8/8/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $93.00
8/8/2025	ANIP ANI Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$94.00
8/7/2025	ARQT Arcutis Biotherapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/25/2025	ARQT Arcutis Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	3.17	$7.71 per share	11.68	$20.16 per share	4.46
ARQT Arcutis Biotherapeutics	$196.54M	9.75	N/A	N/A	$1.16 per share	13.78
SLDB Solid Biosciences	$8.09M	59.39	N/A	N/A	$3.32 per share	1.86
VCEL Vericel	$237.22M	7.61	$0.29 per share	121.38	$6.08 per share	5.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	-$18.52M	-$0.77	N/A	21.38	N/A	-1.37%	25.03%	8.00%	N/A
ARQT Arcutis Biotherapeutics	-$140.04M	-$0.75	N/A	N/A	N/A	-35.40%	-62.62%	-25.16%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-69.70%	-56.74%	N/A
VCEL Vericel	$10.36M	$0.12	298.11	81.30	N/A	2.85%	2.47%	1.69%	N/A

Latest SLDB, ANIP, ARQT, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
8/8/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.42	$1.80	+$0.38	$0.36	$187.18 million	$211.37 million
8/6/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$72.70 million	$81.50 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.39	2.54	1.96
ARQT Arcutis Biotherapeutics	0.77	3.20	3.04
SLDB Solid Biosciences	N/A	9.34	10.89
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
ARQT Arcutis Biotherapeutics	N/A
SLDB Solid Biosciences	81.46%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	11.10%
ARQT Arcutis Biotherapeutics	9.40%
SLDB Solid Biosciences	1.90%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
ARQT Arcutis Biotherapeutics	150	119.90 million	108.63 million	Optionable
SLDB Solid Biosciences	100	77.87 million	76.04 million	Optionable
VCEL Vericel	300	50.46 million	47.84 million	Optionable

SLDB, ANIP, ARQT, and VCEL Headlines

Recent News About These Companies

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13 at 4:25 AM | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12 at 9:08 PM | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Up 308.4% in July

August 5, 2025 | americanbankingnews.com

Vericel FY2025 EPS Forecast Decreased by Leerink Partnrs

August 5, 2025 | americanbankingnews.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What Happened

August 2, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call Transcript

August 2, 2025 | msn.com

Vericel Corporation Reports Strong Q2 2025 Earnings

August 1, 2025 | tipranks.com

Vericel (NASDAQ:VCEL) Shares Gap Down - Here's What Happened

August 1, 2025 | marketbeat.com

Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result

August 1, 2025 | finance.yahoo.com

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, ANIP, ARQT, and VCEL Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$90.00 +1.26 (+1.42%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$89.99 -0.01 (-0.01%)

As of 08/14/2025 05:52 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Arcutis Biotherapeutics NASDAQ:ARQT

$15.98 +0.35 (+2.24%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$15.94 -0.04 (-0.28%)

As of 04:00 AM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Solid Biosciences NASDAQ:SLDB

$6.17 -0.51 (-7.63%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.16 0.00 (-0.08%)

As of 08/14/2025 07:09 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Vericel NASDAQ:VCEL

$35.77 -2.16 (-5.69%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$35.85 +0.08 (+0.22%)

As of 08/14/2025 06:11 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time